Effectiveness of Bokeria—Boldyrev ACH Solution in Surgerical Treatment of Adult Patients with Obstructive Hypertrophic Cardiomyopathy

• Published in: Bulletin of experimental biology and medicine Vol. 169; no. 3; pp. 318 - 323
• Main Authors: Bokeria, L. A., Egorov, D. N., Popov, A. E., Bledzhyants, G. A., Artyukhina, T. V., Movsesyan, R. R.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01-07-2020; Springer
• Subjects: Atrial fibrillation; Biomedical and Life Sciences; Biomedicine; Cardiomyopathy, Hypertrophic; Care and treatment; Cell Biology; Internal Medicine; Laboratory Medicine; Pathology; Surgery, Plastic; Bokeria—Boldyrev ACH cardioplegic solution; obstructive hypertrophic cardiomyopathy; HTK solution (Custodiol); cardioplegia
• ISSN: 0007-4888; 1573-8221
• DOI: 10.1007/s10517-020-04878-7

The study examined effectiveness of
pharmaco-cold cardioplegia
employing solutions of enhanced buffer capacity during surgery of obstructive hypertrophic cardiomyopathy in adult patients (
N
=51) operated during 2013-2018. In group 1 (
N
=28), the cardioplegia was performed with HTK (Custodiol) solution, whereas in group 2 (
N
=23), it was carried out with Bokeria—Boldyrev ACH solution. The mean, minimum, and maximum ages in group 1 were 46, 21, and 64 years, respectively; in group 2 — 42, 14, and 70 years, respectively. In both groups, the patients were subjected to myoectomy of exit pathway in the left ventricle according to Bokeria—Morrow operation and annuloplasty of tricuspid valve accompanied by reconstructive surgery (or replacement) of mitral valve. Atrial fibrillation (if any) was suppressed with cryoablation (-60°С) of the openings of the right and left pulmonary veins. The surgery was carried out in hypothermic mode at 28°C. The significant intergroup differences were observed in the asystole latent period after the onset of antegrade or retrograde injection of cardioplegic solution. In group 1, the asystole latent periods determined after antegrade or retrograde injection were 53±7 or 170±30 sec, respectively; in group 2 — 32±6 and 97±11 sec (
p
<0.0001), respectively. The mean times of aortic cross-clumping in groups 1 and 2 were 66±8 and 64±6 min, respectively; the electromechanical action of the heart restored after aortic unclamping in 35±7 and 30±6 sec, respectively. The biochemical and clinical data revealed no significant intergroup differences. Overall, novel Bokeria—Boldyrev ACH cardioplegic solution secured effective protection of the myocardium against intraoperative ischemia in adult patients with obstructive hypertrophic cardiomyopathy and significantly decreased the asystole latent period.